CEimpact Podcast

An Update on Glucagon

November 07, 2022 CEimpact
CEimpact Podcast
An Update on Glucagon
Show Notes

Less than ten percent of people filled a glucagon prescription after a hospitalization due to hypoglycemia. In the past few years, a slew of new glucagon products have come to market. Join host, Geoff Wall, as he discusses how to optimize glucagon therapy with diabetes expert, Jamie Pitlick.

The GameChanger
Despite glucagon products being proven safe and effective, they are severely under-prescribed and underutilized.  Patients that are at risk for level 2 or 3 hypoglycemia should be prescribed glucagon.

Did you know poisons have been used as murder weapons throughout human history? Join us on November 10th at 7 PM CT for a free, live CE on Murder with Medications exclusively on the CEimpact App. It's free to join! You'll learn about medical professionals who used their access to medications to commit murder. It's fascinating and unimaginable. Sign up here!

Show Segments
00:00 - Introductions

01:54 - The Risk of Hypoglycemia

10:45 - GameChanger: New Glucagon Products

20:40 - Connecting to Practice: What Practitioners Should Know

25:11 - Closing Remarks

Geoff Wall, PharmD, BCPS, FCCP, CGP

Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jamie Pitlick, Pharm.D., BCPS, BC-ADM

Associate Professor, Pharmacy Practice
Drake University College of Pharmacy and Health Sciences

References and Resources

  1. GlucaGen - Plainsboro, NJ: Novo Nordisk.  Revised in March 2021. 
  2. Glucagon - Indianapolis, IN. Eli Lily USA. 
  3. Zegalogue - Denmark: Zealand Pharma. Revised April 2021. 
  4. Baqsimi - Indianapolis, IN: Eli Lily.  Revised October, 2020. 
  5. GVOKE - Chicago, IL: Xeris Pharmaceuticals.   Revised August 2021

Redeem your CPE or CME here

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

CE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the risk of hypoglycemia for patients with diabetes
2. Describe the differences in the glucagon products on the market in the US

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-402-H01-P
Initial release date: 11/07/2022
Expiration date: 11/07/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media: